On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A large multinational cohort study evaluated whether COVID-19 vaccination during pregnancy reduces the risk of preeclampsia, a major hypertensive complication associated with SARS-CoV-2 infection.
Stay up to date with the evolving standards of breast cancer care — our new timeline snapshot highlights the most significant U.S. clinical guideline changes from 2024 to present, including updates from...
A randomized US trial evaluated whether a shortened course of romosozumab followed by denosumab could achieve bone mineral density improvements comparable to the standard 12-month romosozumab regimen in...
A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
Maternal COVID-19 vaccination was linked with fewer severe maternal outcomes; early mRNA vaccination showed no rise in malformations; in utero infection was tied to higher neurodevelopmental diagnoses.
...
